Kyowa Kirin Pharmaceutical Development Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.kyowakirin.com
Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05455931
- Locations
- 🇺🇸
Colombia University Medical Center, New York, New York, United States
🇮🇹Azienda Ospedaliero Universitaria Ospedali Riuniti Do Ancona, Ancona, Italy
🇮🇹IRCCS A.O.U. Policlinico S. Orsola - Malpighi, Bologna, Italy
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
- Conditions
- X-Linked Hypophosphatemia
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT05181839
- Locations
- 🇫🇷
APHP Paris - Assistance Publique Hopitaux de Paris, Paris, France
🇪🇸Hospital General Universitario Santa LucÃa, Cartagena, Murcia, Spain
🇪🇸Hospital Universitario Virgen a de las Nieves, Granada, Spain
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
- Conditions
- X-Linked Hypophosphataemia
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT04819490
- Locations
- 🇬🇧
Royal Hospital for Sick Children, Edinburgh, United Kingdom
🇬🇧NHS Greater Glasgow & Clyde- South Glasgow University Hosp Division, Glasgow, United Kingdom
🇬🇧Evelina Childrens Hospital, London, United Kingdom
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT04188964
- Locations
- 🇦🇹
Kepler Universitaetsklinikum GmbH, Linz, Austria
🇮🇹Ospedale Pediatrico Bambino Gesù, Rome, Italy
🇫🇷Centre de reference des maladies renales rares-Hospices Civils de Lyon-Hopital Femme Mere Enfant, Lyon, France
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 35
- Registration Number
- NCT03920072
- Locations
- 🇮🇹
Azienda ospedaliera universitaria Careggi, Florence, Italy
🇮🇪St. Vincent's University Hospital, Dublin, Ireland
🇫🇷Hopital Lariboisiere, Paris, France
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
- Conditions
- Opioid Induced Constipation
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 183
- Registration Number
- NCT03638440
- Locations
- 🇳🇱
Rijnstate hospital, Arnhem, Netherlands
🇸🇪Skane University Hospital, Lund, Sweden
🇮🇹AORN dei Colli, Napoli, Italy
Registry for Patients With X-Linked Hypophosphatemia
- Conditions
- X-Linked Hypophosphatemia
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 1236
- Registration Number
- NCT03193476
- Locations
- 🇫🇷
"Hopital Pierre-Paul Riquet Centre de Rhumatologie", Toulouse, France
🇫🇷Hopital Purpan, Toulouse, France
🇩🇪Klinikum Ernst-von-Bergmann Potsdam und Bad Belzig, Bad Belzig, Germany
Naloxegol Health Outcome Post Authorisation Safety Study
- Conditions
- Opioid Induced Constipation
- Interventions
- Drug: non-PAMORA laxative
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 10000
- Registration Number
- NCT02813369
- Locations
- 🇬🇧
Research Site, Sutton, Surrey, United Kingdom
Naloxegol Drug Utilization Post Authorisation Safety Study
- Conditions
- Opioid Induced Constipation
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 17254
- Registration Number
- NCT02813148
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Target Recruit Count
- 61
- Registration Number
- NCT02099591
- Locations
- 🇬🇧
Royal Marsden Hospital, London, United Kingdom
🇪🇸Unidad de HematologÃa y OncologÃa Pediátrica - Hospital Universitario HM Monteprincipe, Madrid, Spain
🇳🇴St. Olavs Hospital, Trondheim, Norway